These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 8512801

  • 1. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec 12; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI, Lemmon MJ, Tracy M, Pollart DJ, Martinez AP, Tosto LM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1992 Dec 12; 22(4):701-5. PubMed ID: 1544841
    [Abstract] [Full Text] [Related]

  • 8. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 12; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 9. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH, Minchinton AI.
    Cancer Chemother Pharmacol; 1999 Jul 12; 43(3):213-20. PubMed ID: 9923551
    [Abstract] [Full Text] [Related]

  • 10. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan 12; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 11. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
    Brown JM.
    Br J Cancer; 1998 Jun 12; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
    [Abstract] [Full Text] [Related]

  • 12. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 13. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
    Denny WA, Wilson WR.
    Expert Opin Investig Drugs; 2000 Dec 15; 9(12):2889-901. PubMed ID: 11093359
    [Abstract] [Full Text] [Related]

  • 14. Tirapazamine: laboratory data relevant to clinical activity.
    Brown JM, Wang LH.
    Anticancer Drug Des; 1998 Sep 15; 13(6):529-39. PubMed ID: 9755717
    [Abstract] [Full Text] [Related]

  • 15. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan 15; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 16. Structure-activity relationships for benzotriazine di-N-oxides.
    Zeman EM, Baker MA, Lemmon MJ, Pearson CI, Adams JA, Brown JM, Lee WW, Tracy M.
    Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):977-81. PubMed ID: 2703405
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 18. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT, Greenberg MM, Fuchs T, Gates KS.
    Biochemistry; 1999 Oct 26; 38(43):14248-55. PubMed ID: 10571998
    [Abstract] [Full Text] [Related]

  • 19. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity.
    Kelson AB, McNamara JP, Pandey A, Ryan KJ, Dorie MJ, McAfee PA, Menke DR, Brown JM, Tracy M.
    Anticancer Drug Des; 1998 Sep 26; 13(6):575-92. PubMed ID: 9755719
    [Abstract] [Full Text] [Related]

  • 20. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 26; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.